Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 plus fulvestrant versus placebo plus fulvestrant in HR-positive HER2-negative advanced breast cancer after mTOR inhibitor treatment
NL-OMON44929Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buparlisib and fulvestrant in breast cancer, sponsored by Novartis. Started Dec 2013; status: active, not recruiting.
02
Drugs
buparlisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON44929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44929.